Burrill & Company Advises Aldagen, Inc. (ALDH) in Sale of Its Next Generation Cell Therapy to Cytomedix Inc. (CMXI)
2/21/2012 9:03:47 AM
More...
|
Cytomedix Inc. (CMXI) to Showcase Aldagen, Inc. (ALDH)'s Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings
2/16/2012 8:43:23 AM
More...
|
Cytomedix Inc. (CMXI) Picks Up Aldagen, Inc. (ALDH) for $40 Million
2/9/2012 7:28:05 AM
More...
|
Aldagen, Inc. (ALDH) Presents Data Describing Cell Therapy Products' Mechanism for Homing to Ischemic Injury
1/26/2012 9:00:12 AM
More...
|
Aldagen, Inc. (ALDH) Announces Publication of Mechanism of Action Data for Its Cardiovascular Cell Therapy Products
11/16/2011 8:55:54 AM
More...
|
Aldagen, Inc. (ALDH) Announces First Subject Enrolled and Clears Initial Safety Assessment in Phase 2 Stem Cell Study for Ischemic Stroke
6/2/2011 7:16:37 AM
More...
|
Aldagen, Inc. (ALDH) Announces Publication of Phase 1/2 Results for ALD-301, a Stem Cell Therapy in Development for Critical Limb Ischemia
5/19/2011 9:06:23 AM
More...
|
Aldagen, Inc. (ALDH) Pulls $80.5 Million IPO
4/6/2011 8:30:43 AM
More...
|
Aldagen, Inc. (ALDH) Announces FDA Clearance of IND to Begin Phase 2 Study in Ischemic Stroke With Regenerative Cell Therapy
1/5/2011 10:02:38 AM
More...
|
Aldagen, Inc. (ALDH) Announces Edward L. Field Appointed Vice Chairman of the Alliance for Regenerative Medicine
10/21/2010 9:22:51 AM
More...
|
|